;PMID: 12444089
;source_file_2656.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)section:[e:41..58] = [t:41..58]
;2)sentence:[e:63..150] = [t:63..150]
;3)section:[e:154..186] = [t:154..186]
;4)section:[e:190..285] = [t:190..285]
;5)sentence:[e:289..428] = [t:289..428]
;6)sentence:[e:429..578] = [t:429..578]
;7)sentence:[e:579..794] = [t:579..794]
;8)sentence:[e:795..924] = [t:795..924]
;9)sentence:[e:925..1082] = [t:925..1082]
;10)sentence:[e:1083..1216] = [t:1083..1216]
;11)sentence:[e:1218..1319] = [t:1218..1319]
;12)sentence:[e:1320..1548] = [t:1320..1548]
;13)section:[e:1552..1597] = [t:1552..1597]

;section 0 Span:0..40
;J Biol Chem. 2003 Jan 31;278(5):2837-44.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Biol) (NNP:[7..11] Chem) (.:[11..12] .)
        (CD:[13..17] 2003) (NNP:[18..21] Jan) (CD:[22..24] 31)
        (CD:[24..28] ;278) (-LRB-:[28..29] -LRB-) (CD:[29..30] 5)
        (-RRB-:[30..31] -RRB-) (::[31..32] :) (CD:[32..35] 283)
        (CD:[35..39] 7-44) (.:[39..40] .)))

;section 1 Span:41..58
;Epub 2002 Nov 19.
(SEC
  (FRAG (NNP:[41..45] Epub) (CD:[46..50] 2002) (NNP:[51..54] Nov)
        (CD:[55..57] 19) (.:[57..58] .)))

;sentence 2 Span:63..150
;Protein phosphatase 2A and phosphoprotein SET regulate androgen production by
; P450c17.
;[63..85]:substance:"Protein phosphatase 2A"
;[90..108]:substance:"phosphoprotein SET"
;[118..126]:substance:"androgen"
;[142..149]:cyp450:"P450c17"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (NN:[63..70] Protein) (NN:[71..82] phosphatase) (NN:[83..85] 2A))
      (CC:[86..89] and)
      (NP (NN:[90..104] phosphoprotein) (NN:[105..108] SET)))
    (VP (VBP:[109..117] regulate)
      (NP (NN:[118..126] androgen) (NN:[127..137] production))
      (PP (IN:[138..140] by)
        (NP (NN:[142..149] P450c17))))
    (.:[149..150] .)))

;section 3 Span:154..186
;Pandey AV, Mellon SH, Miller WL.
(SEC
  (FRAG (NNP:[154..160] Pandey) (NNP:[161..163] AV) (,:[163..164] ,)
        (NNP:[165..171] Mellon) (NNP:[172..174] SH) (,:[174..175] ,)
        (NNP:[176..182] Miller) (NNP:[183..186] WL.)))

;section 4 Span:190..285
;Department of Pediatrics, University of California, San Francisco, California
; 94143-0978, USA.
(SEC
  (FRAG (NNP:[190..200] Department) (IN:[201..203] of)
        (NNP:[204..214] Pediatrics) (,:[214..215] ,) (NNP:[216..226] University)
        (IN:[227..229] of) (NNP:[230..240] California) (,:[240..241] ,)
        (NNP:[242..245] San) (NNP:[246..255] Francisco) (,:[255..256] ,)
        (NNP:[257..267] California) (CD:[269..274] 94143) (NNP:[274..279] -0978)
        (,:[279..280] ,) (NNP:[281..284] USA) (.:[284..285] .)))

;sentence 5 Span:289..428
;Cytochrome P450c17 catalyzes 17 alpha-hydroxylation needed for cortisol 
;synthesis and 17,20 lyase activity needed to produce sex steroids.
;[289..307]:cyp450:"Cytochrome P450c17"
;[352..360]:substance:"cortisol"
;[376..387]:substance:"17,20 lyase"
;[419..427]:substance:"steroids"
(SENT
  (S
    (NP-SBJ (NN:[289..299] Cytochrome) (NN:[300..307] P450c17))
    (VP (VBZ:[308..317] catalyzes)
      (NP
        (NP
          (NP (CD:[318..320] 17) (NN:[321..340] alpha-hydroxylation))
          (VP (VBN:[341..347] needed)
            (NP (-NONE-:[347..347] *))
            (PP (IN:[348..351] for)
              (NP (NN:[352..360] cortisol) (NN:[362..371] synthesis)))))
        (CC:[372..375] and)
        (NP
          (NP
            (NML (CD:[376..378] 17) (,:[378..379] ,) (CD:[379..381] 20)
                 (NN:[382..387] lyase))
            (NN:[388..396] activity))
          (VP (VBN:[397..403] needed)
            (NP (-NONE-:[403..403] *))
            (S-PRP
              (NP-SBJ (-NONE-:[403..403] *))
              (VP (TO:[404..406] to)
                (VP (VB:[407..414] produce)
                  (NP (NN:[415..418] sex) (NNS:[419..427] steroids)))))))))
    (.:[427..428] .)))

;sentence 6 Span:429..578
;Serine  phosphorylation of P450c17 specifically increases 17,20 lyase
;activity, but the  physiological factors regulating this effect remain
;unknown.
;[429..435]:substance:"Serine"
;[456..463]:cyp450:"P450c17"
;[487..498]:substance:"17,20 lyase"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[429..435] Serine) (NN:[437..452] phosphorylation))
        (PP (IN:[453..455] of)
          (NP (NN:[456..463] P450c17))))
      (ADVP-MNR (RB:[464..476] specifically))
      (VP (VBZ:[477..486] increases)
        (NP
          (NML (CD:[487..489] 17) (,:[489..490] ,) (CD:[490..492] 20)
               (NN:[493..498] lyase))
          (NN:[499..507] activity))))
    (,:[507..508] ,) (CC:[509..512] but)
    (S
      (NP-SBJ
        (NP (DT:[513..516] the) (JJ:[518..531] physiological)
            (NNS:[532..539] factors))
        (VP (VBG:[540..550] regulating)
          (NP (DT:[551..555] this) (NN:[556..562] effect))))
      (VP (VBP:[563..569] remain)
        (ADJP-PRD (JJ:[570..577] unknown))))
    (.:[577..578] .)))

;sentence 7 Span:579..794
;Treating human  adrenal NCI-H295A cells with the phosphatase inhibitors
;okadaic acid,  fostriecin, and cantharidin increased 17,20 lyase activity,
;suggesting  involvement of protein phosphatase 2A (PP2A) or 4 (PP4).
;[628..639]:substance:"phosphatase"
;[640..650]:substance:"inhibitors"
;[651..663]:substance:"okadaic acid"
;[666..676]:substance:"fostriecin"
;[682..693]:substance:"cantharidin"
;[704..715]:substance:"17,20 lyase"
;[753..775]:substance:"protein phosphatase 2A"
;[753..772]...[786..787]:substance:"protein phosphatase"..."4"
;[777..781]:substance:"PP2A"
;[789..792]:substance:"PP4"
(SENT
  (S
    (S-NOM-SBJ
      (NP-SBJ (-NONE-:[579..579] *))
      (VP (VBG:[579..587] Treating)
        (NP (JJ:[588..593] human) (JJ:[595..602] adrenal)
            (NN:[603..612] NCI-H295A) (NNS:[613..618] cells))
        (PP-MNR (IN:[619..623] with)
          (NP
            (NP (DT:[624..627] the) (NN:[628..639] phosphatase)
                (NNS:[640..650] inhibitors))
            (NP
              (NP (JJ:[651..658] okadaic) (NN:[659..663] acid))
              (,:[663..664] ,)
              (NP (NN:[666..676] fostriecin))
              (,:[676..677] ,) (CC:[678..681] and)
              (NP (NN:[682..693] cantharidin)))))))
    (VP (VBD:[694..703] increased)
      (NP
        (NML (CD:[704..706] 17) (,:[706..707] ,) (CD:[707..709] 20)
             (NN:[710..715] lyase))
        (NN:[716..724] activity))
      (,:[724..725] ,)
      (S-MNR
        (NP-SBJ (-NONE-:[725..725] *))
        (VP (VBG:[726..736] suggesting)
          (NP
            (NP (NN:[738..749] involvement))
            (PP (IN:[750..752] of)
              (NP
                (NP
                  (NP
                    (NML-1 (NN:[753..760] protein) (NN:[761..772] phosphatase))
                    (NN:[773..775] 2A))
                  (NP (-LRB-:[776..777] -LRB-) (NN:[777..781] PP2A)
                      (-RRB-:[781..782] -RRB-)))
                (CC:[783..785] or)
                (NP
                  (NP
                    (NML-1 (-NONE-:[785..785] *P*))
                    (CD:[786..787] 4))
                  (NP (-LRB-:[788..789] -LRB-) (NN:[789..792] PP4)
                      (-RRB-:[792..793] -RRB-)))))))))
    (.:[793..794] .)))

;sentence 8 Span:795..924
;PP2A but not PP4  inhibited 17,20 lyase activity in microsomes from cultured
;cells, but neither  affected 17 alpha-hydroxylation.
;[795..799]:substance:"PP2A"
;[808..811]:substance:"PP4"
;[823..834]:substance:"17,20 lyase"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[795..799] PP2A))
        (CONJP (CC:[800..803] but) (RB:[804..807] not))
        (NP (NN:[808..811] PP4)))
      (VP (VBD:[813..822] inhibited)
        (NP
          (NML (CD:[823..825] 17) (,:[825..826] ,) (CD:[826..828] 20)
               (NN:[829..834] lyase))
          (NN:[835..843] activity))
        (PP-LOC (IN:[844..846] in)
          (NP
            (NP (NNS:[847..857] microsomes))
            (PP (IN:[858..862] from)
              (NP (VBN:[863..871] cultured) (NNS:[872..877] cells)))))))
    (,:[877..878] ,) (CC:[879..882] but)
    (S
      (NP-SBJ (DT:[883..890] neither))
      (VP (VBD:[892..900] affected)
        (NP (CD:[901..903] 17) (NN:[904..923] alpha-hydroxylation))))
    (.:[923..924] .)))

;sentence 9 Span:925..1082
;Inhibition of 17,20 lyase activity by PP2A was  concentration-dependent,
;could be inhibited by okadaic acid, and was restored by  endogenous protein
;kinases.
;[939..950]:substance:"17,20 lyase"
;[963..967]:substance:"PP2A"
;[1020..1032]:substance:"okadaic acid"
;[1066..1081]:substance:"protein kinases"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[925..935] Inhibition))
      (PP (IN:[936..938] of)
        (NP
          (NML (CD:[939..941] 17) (,:[941..942] ,) (CD:[942..944] 20)
               (NN:[945..950] lyase))
          (NN:[951..959] activity)))
      (PP (IN:[960..962] by)
        (NP (NN:[963..967] PP2A))))
    (VP
      (VP (VBD:[968..971] was)
        (ADJP-PRD (NN:[973..986] concentration) (HYPH:[986..987] -)
                  (JJ:[987..996] dependent)))
      (,:[996..997] ,)
      (VP (MD:[998..1003] could)
        (VP (VB:[1004..1006] be)
          (VP (VBN:[1007..1016] inhibited)
            (NP-1 (-NONE-:[1016..1016] *))
            (PP (IN:[1017..1019] by)
              (NP-LGS (JJ:[1020..1027] okadaic) (NN:[1028..1032] acid))))))
      (,:[1032..1033] ,) (CC:[1034..1037] and)
      (VP (VBD:[1038..1041] was)
        (VP (VBN:[1042..1050] restored)
          (NP-1 (-NONE-:[1050..1050] *))
          (PP (IN:[1051..1053] by)
            (NP-LGS (JJ:[1055..1065] endogenous)
               (NN:[1066..1073] protein) (NNS:[1074..1081] kinases))))))
    (.:[1081..1082] .)))

;sentence 10 Span:1083..1216
;PP2A but not PP4 coimmunoprecipitated with P450c17,  and suppression of PP2A
;by small interfering RNA increased 17,20 lyase activity.
;[1083..1087]:substance:"PP2A"
;[1096..1099]:substance:"PP4"
;[1126..1133]:cyp450:"P450c17"
;[1155..1159]:substance:"PP2A"
;[1181..1184]:substance:"RNA"
;[1195..1206]:substance:"17,20 lyase"
(SENT
  (S
    (S
      (NP-SBJ (NN:[1083..1087] PP2A)
        (CONJP (CC:[1088..1091] but) (RB:[1092..1095] not))
        (NN:[1096..1099] PP4))
      (VP (VBD:[1100..1120] coimmunoprecipitated)
        (NP (-NONE-:[1120..1120] *))
        (PP-CLR (IN:[1121..1125] with)
          (NP (NN:[1126..1133] P450c17)))))
    (,:[1133..1134] ,) (CC:[1136..1139] and)
    (S
      (NP-SBJ
        (NP (NN:[1140..1151] suppression))
        (PP (IN:[1152..1154] of)
          (NP (NN:[1155..1159] PP2A)))
        (PP (IN:[1160..1162] by)
          (NP (JJ:[1163..1168] small) (VBG:[1169..1180] interfering)
              (NN:[1181..1184] RNA))))
      (VP (VBD:[1185..1194] increased)
        (NP
          (NML (CD:[1195..1197] 17) (,:[1197..1198] ,) (CD:[1198..1200] 20)
               (NN:[1201..1206] lyase))
          (NN:[1207..1215] activity))))
    (.:[1215..1216] .)))

;sentence 11 Span:1218..1319
;Phosphoprotein SET found in adrenals inhibited PP2A, but not PP4, and
;fostered  17,20 lyase activity.
;[1218..1236]:substance:"Phosphoprotein SET"
;[1265..1269]:substance:"PP2A"
;[1279..1282]:substance:"PP4"
;[1298..1309]:substance:"17,20 lyase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1218..1232] Phosphoprotein) (NN:[1233..1236] SET))
      (VP (VBN:[1237..1242] found)
        (NP (-NONE-:[1242..1242] *))
        (PP-LOC (IN:[1243..1245] in)
          (NP (NNS:[1246..1254] adrenals)))))
    (VP
      (VP (VBD:[1255..1264] inhibited)
        (NP (NN:[1265..1269] PP2A) (,:[1269..1270] ,)
          (CONJP (CC:[1271..1274] but) (RB:[1275..1278] not))
          (NN:[1279..1282] PP4)))
      (,:[1282..1283] ,) (CC:[1284..1287] and)
      (VP (VBD:[1288..1296] fostered)
        (NP
          (NML (CD:[1298..1300] 17) (,:[1300..1301] ,) (CD:[1301..1303] 20)
               (NN:[1304..1309] lyase))
          (NN:[1310..1318] activity))))
    (.:[1318..1319] .)))

;sentence 12 Span:1320..1548
;The identification of PP2A and SET as post-translational  regulators of
;androgen biosynthesis suggests potential additional mechanisms  contributing
;to adrenarche and hyperandrogenic disorders such as polycystic  ovary
;syndrome.
;[1342..1346]:substance:"PP2A"
;[1351..1354]:substance:"SET"
;[1378..1388]:substance:"regulators"
;[1392..1400]:substance:"androgen"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1320..1323] The) (NN:[1324..1338] identification))
      (PP (IN:[1339..1341] of)
        (NP (NN:[1342..1346] PP2A) (CC:[1347..1350] and) (NN:[1351..1354] SET)))
      (PP (IN:[1355..1357] as)
        (NP
          (NP
            (ADJP (AFX:[1358..1362] post) (HYPH:[1362..1363] -)
                  (JJ:[1363..1376] translational))
            (NNS:[1378..1388] regulators))
          (PP (IN:[1389..1391] of)
            (NP (NN:[1392..1400] androgen) (NN:[1401..1413] biosynthesis))))))
    (VP (VBZ:[1414..1422] suggests)
      (NP
        (NP (JJ:[1423..1432] potential) (JJ:[1433..1443] additional)
            (NNS:[1444..1454] mechanisms))
        (VP (VBG:[1456..1468] contributing)
          (PP-CLR (TO:[1469..1471] to)
            (NP
              (NP (NN:[1472..1482] adrenarche))
              (CC:[1483..1486] and)
              (NP
                (NP (JJ:[1487..1502] hyperandrogenic)
                    (NNS:[1503..1512] disorders))
                (PP (JJ:[1513..1517] such)
                  (PP (IN:[1518..1520] as)
                    (NP (JJ:[1521..1531] polycystic) (NN:[1533..1538] ovary)
                        (NN:[1539..1547] syndrome))))))))))
    (.:[1547..1548] .)))

;section 13 Span:1552..1597
;PMID: 12444089 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1552..1556] PMID) (::[1556..1557] :) (CD:[1558..1566] 12444089)
        (NN:[1567..1568] -LSB-) (NNP:[1568..1574] PubMed) (::[1575..1576] -)
        (NN:[1577..1584] indexed) (IN:[1585..1588] for)
        (NNP:[1589..1597] MEDLINE-RSB-)))
